Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Wizz CEO: We’re going to invest $1 b. in Israeli market - 2Spots To Go Birdwatching All over the Planet
- 3April’s full pink moon will rise in the night sky this week
- 4NASA releases new photos of interstellar comet 3I/ATLAS
- 5An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- Green Inflections: A Manual for Inside Plants
- Vote in favor of the wide open action that revives your brain and soul!
- When the moon hits your eye from your Orion ship up high, that's a 'mare'
- Sexual violence is being used as a weapon in Sudan's war, doctors group says
- A Manual for SUVs with Less Noteworthy Gas Mileage
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- Cyprus: War-related tourism concerns and climate change efforts
- Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
